Colorado Bill Proposes Potency-Based Marijuana Tax and Public Health Oversight

DENVER – Colorado lawmakers introduced a bill on Tuesday that would fundamentally overhaul the state’s marijuana industry, proposing to replace the current retail sales tax with a new structure based on product potency and to shift regulatory oversight for testing from the Department of Revenue to public health officials. Senate Bill 161, filed April 16, 2026, represents one of the most significant legislative efforts to reshape Colorado's pioneering cannabis market since its inception. If passed, the measure would eliminate the existing 15% retail marijuana sales tax and establish a new per-milligram tax on intoxicating cannabinoids, a move that would directly tie a product's tax burden to its psychoactive strength. While moving away from a flat 15% sales tax might seem like a simplification, a potency-based system introduces significant new complexities for cannabis businesses. Calculating taxes based on milligram content of active cannabinoids requires meticulous tracking from production to sale, placing a heavy burden on inventory and point-of-sale systems. In our experience, such shifts often lead to unforeseen compliance challenges and cash flow disruptions if not properly managed. This change underscores the critical need for robust tax preparation and compliance strategies tailored to the unique demands of the cannabis industry. Under the proposed legislation, the new tax rates would take effect on January 1, 2027. Edible marijuana products would be taxed at 1.2 cents per milligram of total intoxicating cannabinoids. Inhaled products made with concentrate, those made with marijuana flower, and other intoxicating cannabis products would be taxed at a lower rate of 0.4 cents per milligram. The bill also sets a ceiling on this new tax, capping it at 2 cents per milligram until January 1, 2030, and at 5 cents per milligram thereafter. Additionally, the bill would lower the state's separate retail marijuana excise tax to a flat $1 per pound of unprocessed retail marijuana. Beyond the fiscal changes, the bill calls for a major realignment of regulatory responsibilities. It would transfer authority for product testing and safety from the Marijuana Enforcement Division (MED), which is part of the Department of Revenue, to the Colorado Department of Public Health and Environment (CDPHE). This would empower the CDPHE to set all testing standards, oversee product safety protocols, and establish a new state-run reference laboratory for intoxicating cannabis products. This proposed regulatory shift comes amid long-standing concerns about the integrity of the state's current testing system. According to an analysis by ProPublica, from the beginning of 2023 to the present, half of the 135 final enforcement actions taken by the state against marijuana companies involved problems with product self-sampling and testing. The current system allows manufacturers to select the samples they send to labs for mandatory contaminant testing, a practice critics argue creates opportunities for companies to submit unrepresentative, cleaner samples to ensure they pass. The MED had signaled it was considering changes to this system earlier in the year, a notable reversal from its previous stance. Last year, the agency fought a lawsuit from cultivator Mammoth Farms that sought to force an overhaul of the testing rules. In court filings, the division's lawyers had argued that barring manufacturers from selecting their own samples would be “impracticable.” The introduction of Senate Bill 161 suggests that legislative pressure is now building to mandate such a change. To address these concerns, the bill would require the state to create a statewide off-shelf surveillance testing system. This program would involve regulators randomly testing products pulled directly from dispensary shelves to verify they are free of contaminants and accurately labeled. The legislation also imposes new operational requirements on businesses. Beginning July 1, 2027, all marijuana product producers would be required to register with the CDPHE. Furthermore, the bill mandates public online access to certain data, including adverse health event reports, product testing results, and traceability information, with any personally identifiable information redacted. This transparency measure aims to give consumers and researchers greater insight into the products on the market. The proposed transfer of testing oversight to the Department of Public Health and Environment signals a major philosophical shift, treating cannabis less like liquor and more like a pharmaceutical or food product. For small and mid-sized producers, this means preparing for a more stringent, health-focused compliance regime. We've seen clients struggle when regulatory goalposts move this dramatically, as it impacts everything from standard operating procedures to financial forecasting. Adapting to these new public health mandates will be a significant operational lift, and businesses should proactively review their quality management and reporting systems now. For guidance on navigating these kinds of complex regulatory transitions, business owners can contact C&S Finance Group LLC at csfinancegroup.com. Having been formally introduced in the Senate, the bill will now begin its journey through the legislative process, where it will be subject to committee hearings, debates, and potential amendments. Its progress will be closely monitored by cannabis businesses, public health advocates, and state regulators, as its passage would mark a new chapter for one of the nation's most mature marijuana markets.